Mutual Advisors LLC Increases Stock Position in Bristol Myers Squibb Company (NYSE:BMY)

Mutual Advisors LLC boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 24.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 68,897 shares of the biopharmaceutical company's stock after buying an additional 13,504 shares during the quarter. Mutual Advisors LLC's holdings in Bristol Myers Squibb were worth $4,202,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in BMY. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG bought a new position in shares of Bristol Myers Squibb during the 4th quarter worth $13,094,000. Steward Partners Investment Advisory LLC increased its holdings in Bristol Myers Squibb by 5.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 156,751 shares of the biopharmaceutical company's stock worth $8,866,000 after acquiring an additional 7,624 shares during the last quarter. Exencial Wealth Advisors LLC raised its stake in Bristol Myers Squibb by 8.8% in the 4th quarter. Exencial Wealth Advisors LLC now owns 16,776 shares of the biopharmaceutical company's stock valued at $949,000 after acquiring an additional 1,353 shares during the period. Finally, Souders Financial Advisors lifted its holdings in Bristol Myers Squibb by 9.6% during the fourth quarter. Souders Financial Advisors now owns 6,362 shares of the biopharmaceutical company's stock valued at $360,000 after purchasing an additional 558 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BMY. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Jefferies Financial Group lowered their target price on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Finally, William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $58.00.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the business's stock in a transaction on Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.09% of the stock is currently owned by insiders.

Bristol Myers Squibb Price Performance

NYSE:BMY traded down $0.62 during midday trading on Friday, hitting $47.02. The company had a trading volume of 7,024,133 shares, compared to its average volume of 12,882,565. The stock's fifty day moving average price is $47.75 and its 200-day moving average price is $53.69. Bristol Myers Squibb Company has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The company has a market capitalization of $95.68 billion, a PE ratio of 17.61, a P/E/G ratio of 1.41 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($4.40) EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.27%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.